News and Updates
Press Releases
Seraph 100 Blood Filtration Media May Reduce Tumor-Associated Particles in Blood Samples Drawn From Pancreatic Cancer Patients
ExThera Medical Receives MTEC Award for Pivotal Sepsis Trial
ExThera Announces Completion of Phase I OSCAR I Trial
Revolutionary Trial Aims to Transform Pancreatic Cancer Treatment
Blood Filtration Offers Hope in the Fight Against Pancreatic Cancer
Breakthrough technology study for patients suffering from life-threatening bloodstream infections proceeds into next phase with first patient enrollment
ExThera Medical Announces Formation of New Business Advisory Board
ExThera Medical Taps Current Board Member and Top Finance Executive to Take the Helm
ExThera Medical Awarded U.S. Federal Supply Schedule Contract for Seraph 100 Blood Filter
FDA Grants ExThera Multiple Breakthrough Device Designations for its Seraph® 100 Filter
ExThera Medical Receives Certification for Medical Device Single Audit Program (MDSAP) and Recertification for International Organization for Standardization for Medical Devices (ISO 13485)
ExThera Medical in Growth Mode after FDA Approval of Investigational Device Exemption
ExThera Medical Announces FDA Approval of IDE Application for Use of the ONCObind™️ Extracorporeal Procedure to Remove Circulating Tumor Cells in Patients with Pancreatic Cancer
ExThera Medical Exhibits at the 2023 International Conference on Extracorporeal Organ Support in Zagreb, Croatia
Brooke Army Medical Center (BAMC) Establishes Clinical Utility of Seraph 100 for Critically Ill Patients Suffering from Septic Shock Caused by Multiple Pathogens Including Candida
ExThera Medical Successfully Completes Phase I of PURIFY RCT: US Investigational Device Exemption Trial Evaluating Seraph 100 for the Treatment of Septic Shock
Extracorporeal Blood Filter Removes Circulating Tumor Cells: Dialysis-like Cell Removal Therapy to be Studied for Treating Metastatic Cancer
ExThera Medical’s CEO Bob Ward Receives Prestigious BioMedSA Award for Innovation in Healthcare and Bioscience Including a Groundbreaking Device to Treat COVID-19
ExThera Medical Wins a Gold Edison Award for COVID-19 Innovations: Therapeutic Impact for the Seraph® 100 Blood Filter
Results Published for Seraph 100 Treatment of COVID-19 Confirm Survival Benefit Signal
PURIFY Investigators Announce First Patient Enrolled in a US Randomized Controlled IDE Trial Evaluating Seraph 100 for the Treatment of Septic Shock
ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico
Patient Enrollment is Complete in the DOD-Funded Study of Extracorporeal Hemopurification of Critically Ill COVID-19 Patients
Treatment for critically ill COVID patients results in significant improvement in survival rate according to new study
ExThera Medical and Asahi Kasei Medical Enter into Partnership to Expand Reach of Treatment for the Critically Ill
ExThera and Asahi Kasei Medical secure exclusive distribution agreement in Japan
ExThera Medical Partners with Predicate Healthcare Performance Group to Expand Reach of Proven COVID-19 Treatment
Treatment for Critically Ill COVID Patients Begins 1st Randomized Clinical Trial
Canadian Health Authority Grants ExThera’s Seraph 100 Blood Filter an Interim Order for Treatment of COVID-19
ExThera Expands Distribution of Blood Purification and Pathogen Reduction Treatment for Sepsis and COVID-19 in Europe – ExThera Medical and Fresenius Medical Care to offer Seraph 100 Microbind Affinity Filter in Turkey, Finland, and Estonia
BioMedSA Announces ExThera’s CEO as the Winner of the 2021 Innovation Award in Healthcare and Bioscience
Clinical Trial for Groundbreaking Device to Treat Septic Shock set to Begin
Blood Purification and Pathogen Reduction Treatment for Sepsis and COVID-19 Set for Pan-European Distribution Launch
Seraph 100 Blood Filter Shows Substantially Improved Survival Rates for COVID-19 Patients
Lakhmir Chawla, MD, of Silver Creek Pharmaceuticals, Joins ExThera Medical Board of Directors
Fresenius Medical Care expands critical care offering with ExThera Medical’s Seraph 100 adsorber
Michael Porter of Harvard Business School has Joined the Board of Directors of ExThera Medical Corporation
Seraph® 100 Blood Filter Used by U.S. Department of Defense to Treat COVID-19
DOD to Fund a Multi-Center Randomized Clinical Trial of COVID-19 Treatment with ExThera’s Seraph 100 Blood Filter
US FDA Grants ExThera’s Seraph-100 Blood Filter Emergency Use Authorization for the Treatment of COVID-19 After Promising Results in Europe and the USA
ExThera’s Affinity Blood Filter Is Used to Treat COVID-19 Patients
ExThera Medical Commences Commercial EU Sales of the Seraph® 100 Blood Filter, a Treatment for Drug-Resistant Bloodstream Infections
ExThera Medical Receives CE Mark Approval for the Seraph® 100 Blood Filter: “A Promising Treatment for Drug-resistant Bloodstream Infections and Sepsis”
Dr. Stefan Büttner to Present Clinical Trial Results of ExThera’s Seraph® Pathogen-removing Filter at International Symposium on Intensive Care and Emergency Medicine
ExThera Medical Creates Scientific Advisory Board to Advance the Organization’s Global Clinical Trial Program
ExThera Medical Elects Preston and Dollarhyde to its Board of Directors to Drive the Organization’s Next Phase of Innovation and Growth
MM00025 Rev F